Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(acetylcholine chloride)
88,023 results
  • Radiation dosimetry of the α4β2 nicotinic receptor ligand (+)-[(18)F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results. [Journal Article]
  • EPEJNMMI Phys 2016; 3(1):25
  • Kranz M, Sattler B, … Brust P
  • CONCLUSIONS: Although both enantiomers of [(18)F]flubatine exhibit different binding kinetics in the brain due to the respective affinities, the effective dose revealed no enantiomer-specific differences among the investigated species. The preclinical dosimetry and biodistribution of (+)-[(18)F]flubatine was shown and the feasibility of a dose assessment based on image data acquired on a small animal PET/MR and a clinical PET/CT was demonstrated. Additionally, the first-in-human study confirmed the tolerability of the radiation risk of (+)-[(18)F]flubatine imaging which is well within the range as caused by other (18)F-labeled tracers. However, as shown in previous studies, the ED in humans is underestimated by up to 50 % using preclinical imaging for internal dosimetry. This fact needs to be considered when applying for first-in-human studies based on preclinical biokinetic data scaled to human anatomy.
New Search Next